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Genetically engineered mouse models (GEMMs) of lung cancer closely recapitulate the human disease but suffer
from the difficulty of evaluating tumor growth by conventional methods. Herein, a novel automated image analysis
method for estimating the lung tumor burden from in vivo micro-computed tomography (micro-CT) data is
described. The proposed tumor burden metric is the segmented soft tissue volume contained within a chest
space region of interest, excluding an estimate of the heart volume. The method was validated by comparison with
previously published manual analysis methods and applied in two therapeutic studies in a mutant K-ras GEMM of
non–small cell lung carcinoma. Mice were imaged by micro-CT pre-treatment and stratified into four treatment
groups: an antibody inhibiting vascular endothelial growth factor (anti-VEGF), chemotherapy, combination of anti-
VEGF and chemotherapy, or control antibody. In the first study, post-treatment imaging was performed 4 weeks
later. In the second study, mice were scanned serially on a high-throughput scanner every 2 weeks for 8 weeks
during treatment. In both studies, the automated tumor burden estimates were well correlated with manual
metrics (r value range: 0.83-0.93, P b .0001) and showed a similar, significant reduction in tumor growth in mice
treated with anti-VEGF alone or in combination with chemotherapy. Given the fully automated nature of this
technique, the proposed analysis method can provide a valuable tool in preclinical drug research for screening and
randomizing animals into treatment groups and evaluating treatment efficacy in mouse models of lung cancer in a
highly robust and efficient manner.
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Lung cancer causes more deaths worldwide than any other cancer
type [1,2]. Development of novel therapies to battle lung cancer has
been greatly aided by the emergence of genetically engineered mouse
models (GEMMs) of lung cancer, such as the K-rasG12D;p53Frt/Frt
non–small cell lung carcinoma (NSCLC) model [3], where the
compound effect of conditional mutations in the K-ras oncogene and
the p53 tumor suppressor gene leads to development of adenocar-
cinomas in the mouse lung [4]. GEMMs recapitulate certain aspects
of the human disease associated with the stroma, vascularity, and
immune infiltrate more closely than xenograft models, where tumor
cell lines are implanted in immunocompromised animals [5,6].
However, detection of a therapeutic effect by candidate treatments in
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xenografts, the GEMM lung tumors are not measurable by an
external caliper. Histologic evaluation is time-consuming, spatially
limited within the selected slices, and cannot provide knowledge
about the baseline tumor burden in individual animals before the
treatment is started.
In the clinical setting, computed tomography (CT) is widely used
for detection of lung tumors [7,8]. Image intensities in CT are
quantitative and proportional to the tissue density, which results in
good contrast between solid tumors and the air space (including
airways and alveolar tissue). Micro-CT, which offers higher resolution
than clinical CT systems, has been successfully used for detecting lung
tumors and evaluating tumor burden in mouse lung cancer models,
including preclinical studies of NSCLC GEMMs [3,9–15]. Serial in
vivo imaging of the animals during a treatment study has several
advantages by offering a non-invasive method of screening,
randomizing animals into treatment groups based on baseline
tumor burden, and enabling quantification of treatment effects on
tumor load at different time points within the same animals.
Previously reported methods for quantifying the tumor burden from
micro-CT data have relied on some form of manual input for every
image [3,12]. This typically makes an analysis method time-
consuming, vulnerable to intra-reader and inter-reader variability
and potential reader bias, and generally requires identification of the
tumor tissue by the reader. Semi-automated methods [16–19] have
been reported for segmenting and tracking individual lung nodules,
but there remains a need for a time-efficient method for quantifying
lung tumor burden in a robust manner. Fully automating the image
analysis would offer significant benefits in drug development studies
where objective and reproducible quantification of the tumor
burden is crucial, and high throughput is necessary for gaining
statistical power.
What makes the automation of micro-CT image analysis in the
K-ras mutant;p53 null model challenging is the vast range of tumor
burden during the course of a study [4,12]. The tumor tissue is
indistinguishable by image intensities from other soft tissues in the
thoracic cavity, such as heart, diaphragm, and blood vessels. With
increasing tumor burden, the individual tumors become connected
with other tissues and even manual differentiation of the tumors by a
trained reader becomes challenging. In this study, a novel
automated tumor burden quantification method is introduced.
The method does not rely on differentiation of soft tissue lesions but
rather works by automatically identifying a consistent region within
the rib cage for monitoring changes in the soft tissue content over
time. To account for differences in the heart size between subjects
and time points, a correction is applied in the soft tissue volume
calculation by automatically estimating the heart volume from the
image data and removing it from the total soft tissue volume. The
automated analysis method was validated against a previously
validated manual tumor cross-product analysis method [3] and a
semi-automated volumetric analysis method proposed by Haines
et al. [12]. The new automated method was also applied to a study
that was performed on a high-throughput micro-CT system. Both
studies demonstrated the method’s capability of detecting a
treatment effect of anti-angiogenic therapy by monoclonal
antibodies that inhibit vascular endothelial growth factor (VEGF)
A in a GEMM of NSCLC. An anti-VEGF antibody, bevacizumab
(Avastin), in combination with chemotherapy is used as a standard
of care for advanced NSCLC.Materials and Methods
Genetically Engineered Mouse Model
K-rasLSL-G12D;p53Frt/Frt positive animals were generated as previously
described [3] and maintained on a C57Bl/6J-Tyr strain background.
Tumors were induced in the K-rasLSL-G12D;p53Frt/Frt mice by
infection with 5 × 106 infectious units of Adeno-FLPe/IRES/CRE
at 7 to 9weeks of age. At 16weeks post-infection,mice were randomized
into treatment groups based on micro-CT tumor burden estimates,
body weights, and gender. All animals were dosed and monitored
according to the guidelines from the Institutional Animal Care and
Use Committee at Genentech, Inc (South San Francisco, CA). All
dosing regimens were well tolerated, with no significant body weight
loss or overt signs of toxicity other than those attributable to the
disease itself.
Validation Study
Treatment regimen. Mice in the validation study were dosed as
previously described [3]. Anti-VEGF (B20-4.1.1, mouse IgG2a) and
control (anti-ragweed, mouse IgG2a) antibodies were prepared and
purified at Genentech, Inc. Antibodies were dosed through
intraperitoneal injection at 5 mg/kg twice weekly until the end of
study. Chemotherapy (carboplatin: Paraplatin from Bristol-Myers
Squibb, New York, NY, or generic from Pliva d.d., Zagreb, Croatia.)
was dosed intraperitoneally at 25 mg/kg for the first 5 days of the
study. The treatment groups were control (n = 9), chemo (n = 10),
anti-VEGF (n = 9), and anti-VEGF + chemo (n = 8).
Micro-CT scanning. Micro-CT was performed pre-treatment
and 4 weeks after the start of treatment as described [3]. Briefly,
serial lung imaging was performed on an in vivo micro-CT system
(vivaCT 40; Scanco Medical, Bruettisellen, Switzerland). Data were
acquired at 38-μm isotropic voxel size, 1000 projections, 250-ms
integration time, 45-keV photon energy, and 177-μA current.
During in vivo imaging, the animals were anesthetized with 2%
isoflurane in medical air and kept at a constant 37°C temperature by
regulated warm airflow. The imaging time at each time point was
approximately 25 minutes per animal, and the estimated radiation
dose was 0.2 Gy.
High-Throughput Serial Study
Treatment regimen. Mice in the high-throughput serial study
were dosed similarly to the validation study, with the following
exception: chemotherapy (carboplatin) was given at 60 mg/kg
every 4 days for six doses. The treatment groups were control
(n = 9), chemo (n = 9), anti-VEGF (n = 9), and anti-VEGF + chemo
(n = 9).
Micro-CT scanning. Micro-CT was performed pre-treatment
and 2, 4, 6, and 8 weeks after the start of treatment. The mice
were scanned on an in vivo micro-CT system (eXplore CT120;
Trifoil Imaging, Chatsworth, CA) using an in-house built animal
holder that allows four mice to be scanned simultaneously. The
scanning parameters were 900 projections per full rotation, 16-ms
integration time, 75-keV photon energy, 40-mA tube current, and
4 × 4 detector binning. The lung images from the four mice were
reconstructed within individual regions of 275 × 275 × 300 voxels
and 100-μm isotropic voxel size. The animals were anesthetized
with 2% isoflurane in medical air, and the scan time was
approximately 5 minutes per four mice resulting in an average scan
time of 1.25 minutes per mouse.
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The image analysis methods for data from the two different
scanners are essentially identical but accommodate for scanner-
dependent differences in image intensities, voxel dimensions, and
smoothness of the images where applicable. The micro-CT image
intensities were converted to Hounsfield units (HU) according to
the scanner manufacturers’ calibration methods. For intensity
thresholding procedures, the threshold values were chosen empirically
to optimize algorithm performance and differ somewhat between
the scanners. Scanner-dependent differences in HU values are
commonly caused by differences in the X-ray energy spectrum, the
scanner geometry, and the detector’s non-linearity [20,21].
Cross-Product Analysis. The manual cross-product analysis of
micro-CT images for tumor burden quantification was performed as
described previously [3]. Image data were evaluated using Analyze
image analysis software (AnalyzeDirect, Lenexa, KS). The lung
micro-CT data were viewed in the coronal plane to identify tumors.
The largest cross-sectional plane of each tumor was determined by
the reader, from which estimates of maximal tumor diameter (d1)
and the largest perpendicular diameter (d2) were determined by
placing a ruler on the screen. The total tumor burden was defined as
the sum of the cross-products (SCP) of the directional estimates of
all tumors per animal: SCP = ∑(d1 × d2). This in vivo micro-CT
tumor analysis method has been previously validated by ex vivo
micro-CT analysis [3].
Tracing Analysis. The tumor burden was also quantified with
a manual tracing method of micro-CT images that was based on
a previously proposed method by Haines et al. [12]. The total
intra-thoracic space within the rib cage, excluding heart,
mediastinum, liver, and diaphragm, was segmented with Analyze
software by manually drawing regions in the transverse plane on
approximately eight evenly spaced slices and propagating (linear
interpolation) between the regions to include all slices in the
region of interest (ROI).
Soft, non-alveolar tissue was automatically segmented as follows:
The image data from the vivaCT 40 scanner were low-pass filtered by
a 3 × 3 × 3 mean filter, intensity-thresholded, and morphologically
filtered (opened and closed with a 3 × 3 × 3 kernel) [22]. The image
data from the eXplore CT120 were segmented by intensity
thresholding only. The threshold range for the segmentation was
chosen empirically based on visual inspection of a small set of
animals (vivaCT 40: −260 to 580 HU, eXplore CT120: −280 to
100 HU). The soft tissue was then masked with the ROI to calculate
the tumor and vasculature volume (TVV). Since the vascularOriginal Image
Find TB
Find HDI
Segment chest space
Segment soft tissue
Figure 1. Automated image analysis method for lung tumor burden qu
starting with the original micro-CT image of the lung. The 3D ROI is b
contoured on transverse slices to define the chest space. Soft tissue v
automatically estimated volume of the portion of heart that is includportion of TVV is expected to remain relatively constant, changes
in TVV are expected to predominantly stem from tumor growth
or regression.
Automated Analysis. The automated image analysis algorithm
for estimating the lung tumor burden was written in C++ language
using the AVW function libraries (AnalyzeDirect) and was based on
intensity thresholding and morphologic operations. An overview of
the method is presented in Figure 1. The guiding principle is to
automatically identify a consistent ROI bounded by anatomic
landmarks, so that the same region of the lung is included in the ROI
even if the lung shape or size changes, which can occur due to lung
expansion associated with greater tumor burden. The ROI is
confined to be within the rib cage in the transverse plane and between
the tracheal bifurcation (TB) and the interface between the heart and
the diaphragm in the axial direction. Soft tissue is then segmented
within the ROI by employing the same thresholding values and
morphologic filtering as described above for the tracing analysis. The
goal was also to eliminate variability in the amount of included
non-tumor tissue. Since the heart is a major component of the soft
tissue within the ROI, an algorithm was developed to estimate the
included heart volume, which is then subtracted from the total tissue
volume. The specific steps of the algorithm are described below in the
following sections.
Finding the anterior and posterior extents of the lung. A flowchart
illustrating the algorithm for finding the transverse slice locations for
the anterior (TB) and posterior [heart-diaphragm interface (HDI)]
ends of the ROI is shown in Figure 2A. Before these steps, the vivaCT
40 images were median filtered (5 × 5 × 5), whereas the eXplore
CT120 images were analyzed unfiltered.
TB detection algorithm. The transverse slice location for the
TB defining the anterior end of the ROI is determined as follows:
First, a body mask of the mouse is created by intensity thresholding the
image (vivaCT 40: −470 HU, eXplore CT120: −400 to 2000 HU),
finding the largest three-dimensional (3D) object of six-connected
voxels, and filling eight-connected holes on 2D transverse slices. The
lung air space (including alveolar tissue) is segmented by intensity
thresholding (upper threshold, vivaCT 40: −470 HU, eXplore
CT120: −400 HU) the image, where the body mask is applied to
exclude the air outside the mouse. Starting from the anterior end of
the binary lung air space image, going in the posterior direction,
transverse 2D slices are examined by finding objects of eight-connected
pixels of the air space. The trachea appears as the only connected
object of the air space until the bifurcation is reached, where a newROI
Estimate heart size
Calculate total 
tissue volume Automated
Tissue 
Volume
antification. The flowchart illustrates the main steps of the method,
ounded by anatomic landmarks: TB, HDI, and the rib cage, which is
olume is calculated within the ROI and corrected by subtracting an
ed in the ROI, resulting in the tumor burden metric: ATV.
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Figure 2. Automated detection of the axial extents of the ROI. (A) A flowchart illustrating the algorithm for finding the transverse slice
locations for the posterior (HDI) and anterior (TB) ends of the chest space ROI. At the HDI slice, the air space area is at its maximum in the
transverse plane. The TB slice is determined by examining transverse 2D slices of the air space image starting from the anterior end of the
lung. C to E show transverse cross sections of the micro-CT data at different slice locations that are indicated on a coronal cross section
(B). The corresponding images of segmented lung air space (black) within the bodymask (white) are shown in F to H. Connected air space
objects on each slice are identified (arrows on F–H). At first, the trachea appears as the only object (F). If a new object appears (G), but the
objects are further than 0.5 mm apart from each other, the algorithm continues. At the TB slice (H), the trachea object splits into two
closely spaced objects (left and right bronchi).
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detection from other possible objects, such as a lobe of the lung, is
that the two objects (left and right bronchi) have to be within 0.5 mm
from each other at the TB slice. The procedure is illustrated in
Figure 2.
HDI detection algorithm. At the posterior end of the lung, it is
important to exclude the diaphragm from the ROI. The air space area
is calculated on transverse 2D slices of the segmented lung air space
images. Starting from the slice at the posterior end of the lung, going
in the anterior direction, the air space area increases rapidly and
reaches a maximum when the diaphragm disappears. From that point
forward, the tapering of the lung and increasing heart area cause the
air space area to decrease. This maximum in air space area defines the
HDI, which is chosen as the posterior end of the ROI.
Segmentation of the chest space. The rib cage is segmented by first
applying a lower intensity threshold (vivaCT 40: 840 HU, eXplore
CT120: 175 HU) and a morphologic close (vivaCT 40:5 × 5 × 5,
eXplore CT120:3 × 3 × 3) operation to the original image to segment
the bone and then combining six-connected voxels into 3D objects.
The largest connected object is kept and it includes the ribs, vertebrae,
and sternumbut excludes the scapula and the front limb bones.On each
transverse 2D slice of the rib cage image between the TB and the HDI,
connected pixels are combined into objects and the innermost (closest
to the bodymask centroid) points of these objects are used for creating a
mask of the chest space. The points are first ordered clockwise by their
direction from the centroid of the body mask. If any two points form a
low angle of less than 12° between them (measured from the bodycentroid) and are located on the dorsal side of themouse, the further one
is removed from the point list. The distant points thatmeet these criteria
are typically from further sections of the vertebrae and could cause
undesirable effects in the following step if not removed (Figure 3). The
remaining points are then connected by fitting a smooth closed curve
trace (spline) to them. The area bounded by the trace is morphologically
filled to create a binary mask of the chest space. The resulting 3D chest
space ROI is axially smoothed by applying a 1 × 1 × 5median filter and a
1D gap-filling operation in the axial direction.
The soft tissue is segmented by employing the same thresholding
and morphologic filtering procedures as described under the Tracing
Analysis section, and the tissue volume is calculated within the
automatically detected chest space ROI.
Estimating the heart size. The heart is indistinguishable from the
tumor tissue by image intensities. Moreover, tumors can be attached
to the heart without a visible boundary, making it very difficult to
segment the entire heart in the images automatically and robustly.
Therefore, our approach is to get an estimate of the shortest principal
axis length of the heart and employ this in a model to estimate the
total heart volume. The estimate of shortest principal axis does not
require a well-defined boundary encompassing the entire heart.
The chest space mask from the previous step is dilated by 20 voxels to
insure that the heart would be entirely enclosed in it. The segmented soft
tissue image is morphologically closed (3 × 3 × 3) and masked with the
dilated chest space mask, and the heart radius is estimated by fitting the
largest possible sphere within the masked soft tissue. The sphere is
bounded by the ribs and sternumon the ventral side and the lung air space
BA With angular filtering Without angular filtering
Figure 3. Illustration of the automated chest space segmentation. The innermost points of the bones on transverse slices are first ordered
by the angle they form from the body center. Measured from the body center, if any two points form a low angle of less than 12° between
them and are located on the dorsal side, the further one is removed from the point list. The remaining points are then connected by a
smooth closed spline (shown in red) that is filled to create the chest space mask (A). If no angular filtering was applied to the points, the
mask would be too inclusive in this case (B).
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bronchi typically remain around the heart to limit the boundaries.
Furthermore, to limit the effect of a possible overestimation of the heart
size due to significant tumor growth, an upper limit of 3.6mm is imposed
on the heart radius. This value was chosen as rm + 2 * SD, where themean
radius (rm = 3.2 mm) and the standard deviation (SD = 0.2 mm) of the
radius were measured in non–tumor-bearing mice in a separate study.
The heart is modeled as a skewed ellipsoid with the principal axes
lengths a = 2r, b = 2.6r, and c = 3.2r, where r is the heart radius
estimated by the algorithm. The volume of the heart included in the
ROI is calculated with the equation below as the volume (V) of an
ellipsoidal cap, the height of which is the axial ROI length (L):
Ellipsoidal cap volume : V ¼ ab
3c2
L2 3c−Lð Þ: ð1Þ
Figure 4 illustrates the skewed ellipsoid with the directions of its
two longest principle axes and its relation to the axial extents of the
ROI (TB and HDI). Finally, the ellipsoidal cap volume is subtracted3.2r
2.6r
TB
HDI L
Figure 4. Estimating the heart volume. A large portion of the heart is
included heart is estimated bymodeling it as a skewed ellipsoidal cap
are 3.2r, 2.6r, and 2r, where r is the radius of the maximum sphere tfrom the tissue volume in the rib cage to calculate the automated
tissue volume (ATV).
The validity of the automated heart size estimates was confirmed
by manually tracing the hearts in the validation study. The heart
boundaries were traced on six to eight transverse slices between the
identified TB and HDI slices and propagated between the traces. The
traced heart volumes were compared against the ellipsoidal cap
volumes calculated in the previous step.
Quality control and manual corrections. If the algorithm fails in
determination of the TB or HDI or in segmentation of the rib cage, it
is important to detect the failure and enable manual correction in a
way that is compatible with the automated results from other scans.
The analysis program creates a 3D surface rendering from the image
that shows the ROI in relation to the skeleton as shown in Figure 5.
These renderings can be quickly reviewed to determine if the ROI is
appropriately located within the rib cage. The analysis software also
includes an automatic range checking for the axial length of the ROI.2.6r
2r
included within the automatically defined ROI. The volume of the
of length L between the TB and HDI. The dimensions of the ellipsoid
hat fits inside the heart.
Figure 5. Automatically defined ROI for quantifying the lung tumor burden. Surface rendering of the ROI (red) defined by the automated
method is shown in relation to the mouse skeleton. These renderings are automatically generated by the analysis program and used for a
visual check of the ROI as part of the quality control procedure.
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manually examined for possible failure in the TB or HDI detection.
In case of failed TB or HDI detection, the user manually indicates the
correct TB and HDI slice locations, and the rib cage is segmented by
the algorithm. If the rib cage mask is incorrectly segmented, the user
traces the inside of the rib cage on six to eight evenly spaced slices
between the TB and HDI, and the ROI is completed by propagating
between the traces.
Statistical analysis. All data values presented are mean ± SD, and
the error bars on the graphs represent standard error of mean (SEM).
All statistical analyses were performed with JMP 11 software (SAS,
Cary, NC). Pearson linear correlation coefficient (r) was calculated
to compare ATV with the manual tumor burden metrics (SCP and
TVV). Since SCP is a cross-sectional tumor area metric while ATV is
a 3D metric, the Spearman rank correlation coefficient (rs) was also
calculated. The change in tumor burden metrics from baseline
(ΔSCP, ΔTVV, and ΔATV) was used as a metric of treatment
efficacy, and the treatment groups were compared against the
control group using the Dunnett test, with P values less than .05
considered significant.
Results
Validation Study
In the validation study, mice were scanned on the micro-CT
pre-treatment and 4 weeks after start of the treatment. Tumor
burden was evaluated from the image data by the automated method
and compared to the two manual analysis methods: cross-product
analysis and tracing analysis, which were performed by a single
reader (H.B.-R.). For the automated analysis, 12 of the 72 data sets
required a manual correction to indicate either the anterior or the
posterior end slice, or the outline of the rib cage. Corrections were
done by a single reader (K.H.B.). A representative image of the ROI
defined by the automated method in the validation study is shown
in Figure 5.
The mean values for the different tumor burden metrics of all mice
at pre-treatment and post-treatment time points were, respectively,
ATV: 269±145 mm3, 334±172 mm3; TVV: 211±164 mm3, 286±192 mm3; SCP: 39±29 mm2, 51±33 mm2. Scatterplots of ATV
versus SCP and TVV and of ΔATV versus ΔSCP and ΔTVV are
shown in Figure 6. The ATV was well correlated with both SCP (r =
0.88, rs = 0.81, P b .0001) and TVV (r = 0.93, P b .0001). The
change in ATV from baseline (ΔATV) was also well correlated with
both ΔSCP (r = 0.83, rs = 0.74, P b .0001) and ΔTVV (r = 0.90, P b
.0001). From the scatterplot between ATV and SCP (Figure 6A), it
can be seen that in the absence of visible tumors (SCP = 0 mm2),
ATV had a bias value of approximately 100 mm3 from non-tumor
soft tissues that are included in the ROI. TVV also has a bias volume,
which is lower (approximately 50 mm3) due to the differences in the
included regions between the automated and tracing methods, such as
the mediastinum and soft tissue at the anterior end of the lung that
were excluded in the tracing analysis for TVV.
The automated estimates of heart volumes correlated well with the
manual estimates (r = 0.84, P b .0001; Figure 7) and had similar
mean values (automated: 256 ± 39 mm3, manual: 254 ± 33 mm3).
The average minimum heart radius estimated by the algorithm was
3.2 ± 0.2 mm. A small but statistically significant reduction in the
heart radius estimate from pre-treatment to post-treatment was
observed in the anti-VEGF + chemo group (−3%, P b .05, paired
t test) but not in the other groups.
A correlative relationship was observed between the chest space
volume and tumor burden, evidenced by a positive correlation
between the volume of the automatically generated ROI and SCP (r =
0.79, P b .0001; Figure 8A). The change in the ROI volume in
individual animals during the study was also correlated with the
change in SCP (r = 0.74, P b .0001; Figure 8B). The air space volume
within the ROI, calculated by subtracting the segmented tissue
volume from the ROI volume, did not correlate with the tumor
burden (r = 0.23, P N .05; Figure 8C). This shows that the chest space
volume in the mice got larger as their tumor burden increased, while
the air space volume was not affected.
All tumor burden metrics showed significant reduction in tumor
growth in both the anti-VEGF group (ΔSCP: −90%, P b .001,ΔTVV:
−69%, P b .01, ΔATV: −68%, P b .01) and the anti-VEGF + chemo
group (ΔSCP: −87%, ΔTVV: −94%, ΔATV: −99%, P b .001 for all)
compared to the control group (Figure 9).
A B
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r = 0.88, rs = 0.81
r = 0.83, rs = 0.74
r = 0.93
r = 0.90
Figure 6. Comparison of the ATV to manual tumor burden metrics, SCP and TVV, of all scans in the validation study. ATV showed good
correlation to both SCP (A) and TVV (B). The change in ATV from baseline (ΔATV) was also well correlated with ΔSCP (C) and ΔTVV (D). P b
.0001 for all correlations.
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In the high-throughput study, mice were imaged every 2 weeks for
8 weeks from the start of treatment on week 16 post-infection. All
mice (n = 9 per group) were alive on weeks 16 and 18. At the
following time points, the numbers of surviving animals for each
group were (control, chemo, anti-VEGF, anti-VEGF + chemo,
respectively) eight, nine, nine, and nine for week 20, six, three, eight,
and nine for week 22, and four, two, seven, and nine for week 24.
Tumor burden was evaluated with the automated method as well
as the manual tracing method for comparison. The automated ROI’s
were corrected for 9 of the 155 data sets by a single reader (K.H.B.).
Mice were randomly assigned to two readers (J.E.L. and R.M.) for
tracing analysis, and all time points for each mouse were read by ther = 0.84, p < 0.0001
Figure 7. Validation of the automated heart volume estimates.
Heart volumes estimated by the automated method (on y-axis)
were validated against manual tracing (on x-axis). The volume
estimates showed similar values and good correlation.same person. Good correlations were observed between ATV and
TVV (r = 0.90, P b .0001; Figure 10A) and between ΔATV and
ΔTVV (r = 0.85, P b .0001; Figure 10B), similar to the validation
study. Figure 11 shows the time courses (mean ± SEM) of ΔATV and
ΔTVV for each group. The control group and chemo group were not
plotted past week 20 as they were missing significant numbers of mice
compared to the earlier time points due to high attrition rates for
these two groups. Starting from week 18, both ΔATV and ΔTVV
were significantly reduced in anti-VEGF group (ΔATV: P b .005,
ΔTVV: P b .05 for all time points) and anti-VEGF + chemo group
(ΔATV: P b .0001, ΔTVV: P b .005 for all time points), and ΔATV
was significantly reduced for the chemo group (P b .05 for all time
points) when compared to control (Dunnett test). Similarly to the
finding in the validation study, the heart radius estimate in the
anti-VEGF + chemo group was reduced from baseline at all four
post-treatment time points (−7%, −8%, −7%, −4%, P b .005,
paired t test).Discussion
In this manuscript, a novel automated image analysis method for
estimating the lung tumor burden in an NSCLC GEMM imaged by
in vivomicro-CT has been introduced. The general principle of using
segmented soft tissue within an ROI in the lung is similar to the
method proposed by Haines et al. [12], but instead of manually
contouring the ROI, the algorithm presented here automatically finds
fixed anatomic landmarks (TB, HDI, and rib cage) that define the
ROI boundaries. The algorithm also estimates the heart size and
subtracts it from the tissue volume. The obvious advantage of
automating the analysis is saving time, but perhaps even more
importantly, it makes the analysis objective and reproducible. The
A B C
r = 0.79, p < 0.0001 r = 0.74, p < 0.0001 r = 0.23, p > 0.05
Figure 8. Evidence of chest space volume increase due to tumor growth. (A) The volume of the automatically generated ROI (on the y-axis)
was larger at higher tumor burden (SCP on the x-axis). (B) The change in the ROI volume from pre-treatment to post-treatment in individual
mice was also correlated with the change in tumor burden. However, the air space volume within the ROI did not depend on the tumor
burden (C). This shows that the chest space volume in the mice increased with increasing tumor burden. The mice likely compensate for
the space taken up by the tumors by increasing the chest space to maintain adequate functional lung capacity and ventilation.
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tumors from other soft tissue, which becomes challenging when large
tumors grow attached to the heart and the diaphragm. This situation
can also cause the automated method to overestimate the heart radius,
but the effect of this is limited by imposing a maximum limit for the
radius. In these cases, the tumor burden is large and the error from
not having an accurate heart size estimate becomes relatively small.
Conversely, at low tumor burden when accurate heart size estimates
are more important for reducing variability, the algorithm is also more
likely to be accurate since there is less chance of a large tumor being
attached to the heart.
The method was validated by comparison against two previously
validated manual analysis techniques: the cross-product method [3]
and the tracing method, which was based on a description by Haines
et al. [12]. Unidimensional or bidimensional measurements of
tumors, similar to the cross-product method used here, are typically
used in clinical setting to evaluate tumor progression [23,24]. The
cross-product analysis is particularly challenging when tumors start
connecting to each other and are difficult to tell apart. Measuring
previously separated tumors as one contiguous tumor may lead to
underestimating the tumor burden. The volumetric methods are notA B
** **
Figure 9. Treatment efficacy in the validation study. Treatment effec
tumor burden metrics (A) ΔSCP, (B) ΔTVV, and (C) ΔATV, from pre-tre
Points show individual animals, the horizontal lines are the group mea
to control by Dunnett test: *P b .01, **P b .001.hindered by this but are less sensitive at detecting a single small
nodule in the lung due to variability in the other included soft tissues.
The comparison of tumor volumes with the SCP is somewhat
complicated by their non-linear relationship. Nevertheless, the tumor
burden measured by all three methods correlated well and showed
similar therapeutic responses.
The automated method was also applied to a study that was
performed on a high-throughput micro-CT scanner where four mice
can be simultaneously scanned in 5 minutes. This allows completing
the scanning and analysis of more than 100 mice per day by a single
person. A good correlation between automated and manual tissue
volumes was observed in this study as well, and the automated
method showed a similar treatment effect on tumor growth by
anti-VEGF therapy alone and in combination with chemotherapy,
as was also observed in the validation study. A small reduction in
tumor growth was also observed by chemotherapy alone, which
could be a result of using a more aggressive chemotherapy regimen in
this study.
In tumor-bearing mice, the lung morphology changes as the disease
progresses. An increase in the chest space volume was observed with
increasing tumor burden, as has been previously reported by HainesC
* ** * **
t on tumor growth was evaluated by comparing change (Δ) in the
atment to post-treatment imaging (4 weeks later), between groups.
ns, and the error bars are SEM. Treatment groups were compared
A B
r = 0.89 r = 0.90 
Figure 10. Comparison of tissue volume metrics in the high-throughput serial study. (A) ΔATV and manually traced ΔTVV values and (B)
change from baseline, ΔATV and ΔTVV. P b .0001 for both correlations.
134 Quantification of Tumor Burden Barck et al. Translational Oncology Vol. 8, No. 2, 2015et al. [12]. This volume increase is likely due to a compensatory
response to maintain adequate functional air space and ventilation as
the lung becomes occupied by the growing tumors. To include the
same lung regions in the ROI, it is important to define the ROI by
anatomic landmarks that relate to the lung itself and not only the
skeletal structures around it.
In both studies, a reduction was observed in the minimum heart
radius estimated by the algorithm in mice treated with a combination
of anti-VEGF and chemotherapy. Further investigation would be
required to determine the cause of the reduction and whether it relates
to a change in the heart muscle tissue volume, blood volume, or some
physiological alteration in diastolic volume that results in apparent
size change in the heart. No significant changes in heart size were
observed in the other groups. This shows the importance of
estimating the heart size, not only to reduce variability but also to
avoid biasing results by a potential drug effect on the heart.
In the presented studies, a manual correction to accurately identify
the bounding anatomic structures (rib cage, TB, or HDI) was needed
in less than 10% of all scans (validation study: 16.7%, high-A B
Figure 11. Treatment efficacy in the high-throughput serial study. T
volume measured by both (A) automated method and (B) manual tra
test) by both anti-VEGF and anti-VEGF + chemo therapies starting on
After week 20, the control and chemo groups are not shown on the
show group mean ± SEM.throughput study: 5.8%). The correction typically takes less than 5
minutes per scan to complete. Errors in the rib cage segmentation can
result from image artifacts caused by a shift in the mouse position
during the scan but not by regular breathing motion. The TB or HDI
detection can fail due to heavy tumor burden obstructing one of the
bronchi at the TB or filling the area around the HDI. These situations
can be identified and corrected by the user following the steps
outlined in the Quality control and manual corrections section. Even
when manual input is required, the method limits the possible
variability from reader interpretation since the bounding anatomic
structures are relatively unambiguous to identify and the reader is
typically not required to distinguish tumor tissue from other identical
appearing soft tissue. Consequently, the intra-reader and inter-reader
variability and manual versus automated variability are expected to be
small, although they were not evaluated in this study. In rare
situations where the tumor burden is so severe that even the reader
cannot determine the HDI, it is recommended to match the number
of included slices (TB to HDI) between the baseline and later scans so
that approximately the same regions in the lung are included.reatment started on week 16 post-infection. The change in tissue
cing method showed significant treatment effect (P b .05, Dunnett
the first post-treatment imaging time point (week 18 post-infection).
graphs due to losing significant numbers of the mice. Data points
Translational Oncology Vol. 8, No. 2, 2015 Quantification of Tumor Burden Barck et al. 135The presented automated method does not address a potential
heterogeneity of treatment response in tumors, which would require
identification and measurement of individual tumors at different time
points. Another limitation of the method is that the portion of the
lung posterior to the HDI is excluded from the analysis and any
tumors located in this region would therefore not contribute to the
tissue volume. The excluded lung region is approximately 15% of the
entire chest space volume and typically contains less than 25% of the
tumors. As shown by the correlation and similar treatment responses
between ATV and TVV, this omission did not significantly affect the
results, but it may be a concern in a model that exhibits a low tumor
burden. Improving the inclusion would require detecting the curved
surface of the diaphragm, which can vary in shape and angle.
In conclusion, a novel automated analysis method was developed
for quantifying the tumor burden from micro-CT images in an
aggressive K-ras–driven GEMM of NSCLC where tumors can invade
significant portions of the lung. The method should be readily
applicable to other orthotopic mouse lung tumor models as well. The
rapid and robust nature of this analysis method, combined with
high-throughput micro-CT scanning, can provide a valuable tool in
preclinical drug research for screening and randomizing animals into
treatment groups as well as evaluating treatment efficacy non-invasively
in GEMMs of lung cancer.
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